Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Moumen, Mejdi ^a,b   Chiche, Aurélie ^a,b   Decraene, Charles ^a,b   Petit, Valérie ^a,b   Gandarillas, Alberto ^c,d   Deugnier, Marie Ange ^a,b   Glukhova, Marina A ^a,b   Faraldo, Marisa M ^a,b  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d INSERM   (France)

Author keywords

catenin signaling; Basal like breast cancer; Mammary gland; Myc; Stem cells

Indexed keywords

BETA CATENIN; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL CELL; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST TUMOR; CANCER STEM CELL; CONTROLLED STUDY; EPITHELIUM BASAL CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; STEM CELL EXPANSION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; BETA CATENIN; CARCINOGENESIS; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE DELETION; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 84887914209     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-132     Document Type: Article

References (50)

1. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012, 12:96-110. 10.2174/156652412798376134, 3343384, 22082486.
2. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823. 10.1016/S0140-6736(11)61539-0, 22098854.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
4. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
5. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
6. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009, 117:273-280. 10.1007/s10549-008-0197-9, 18815879.
7. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008, 22:2755-2766. 10.1101/gad.1712408, 2751281, 18923074.
8. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer 2010, 1:629-640. 10.1177/1947601910378691, 3092228,3092228, 21779462.
9. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 2009, 4:e4710. 10.1371/journal.pone.0004710, 2650420, 19270750.
10. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012, 209:679-696. 10.1084/jem.20111512, 3328367, 22430491.
11. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010, 143:313-324. 10.1016/j.cell.2010.09.010, 3018841, 20946988.
12. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69:5364-5373. 10.1158/0008-5472.CAN-08-4135, 2782448, 19549913.
13. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176:2911-2920. 10.2353/ajpath.2010.091125, 2877852, 20395444.
14. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
15. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88. 10.1038/nature04372, 16397499.
16. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
17. van Amerongen R, Bowman AN, Nusse R. Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 2012, 11:387-400. 10.1016/j.stem.2012.05.023, 22863533.
18. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011, 479:189-193. 10.1038/nature10573, 21983963.
19. Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010, 6:568-577. 10.1016/j.stem.2010.03.020, 2917779, 20569694.
20. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:e1000121. 10.1371/journal.pbio.1000121, 2683567, 19492080.
21. Plaks V, Brenot A, Lawson DA, Linnemann JR, Van Kappel EC, Wong KC, de Sauvage F, Klein OD, Werb Z. Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis. Cell Rep 2013, 3:70-78. 10.1016/j.celrep.2012.12.017, 3563842, 23352663.
22. Moumen M, Chiche A, Deugnier MA, Petit V, Gandarillas A, Glukhova MA, Faraldo MM. The proto-oncogene Myc is essential for mammary stem cell function. Stem Cells 2012, 30:1246-1254. 10.1002/stem.1090, 22438054.
23. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 2005, 132:267-277. 10.1242/dev.01583, 15590737.
24. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
26. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D. How different are luminal a and basal breast cancers?. Int J Cancer 2009, 124:1338-1348. 10.1002/ijc.24055, 19058218.
27. Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 2012, 10:183-197. 10.1016/j.stem.2011.12.018, 3277444, 22305568.
28. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev 2010, 20:91-95. 10.1016/j.gde.2009.11.001, 2822095, 19962879.
29. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003, 100:15853-15858. 10.1073/pnas.2136825100, 307657, 14668450.
30. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P. MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One 2009, 4:e4537. 10.1371/journal.pone.0004537, 2639708, 19225568.
31. Visvader JE. Cells of origin in cancer. Nature 2011, 469:314-322. 10.1038/nature09781, 21248838.
32. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417. 10.1016/j.stem.2010.07.010, 20804975.
33. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2012, 109:2772-2777. 10.1073/pnas.1017626108, 3286919, 21940501.
34. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955. 10.1073/pnas.1102454108, 3093533, 21498687.
35. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38. 10.1016/j.cell.2012.12.012, 23273993.
36. Incassati A, Chandramouli A, Eelkema R, Cowin P. Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res 2010, 12:213. 10.1186/bcr2723, 3046427, 21067528.
37. Rowlands TM, Pechenkina IV, Hatsell SJ, Pestell RG, Cowin P. Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia. Proc Natl Acad Sci USA 2003, 100:11400-11405. 10.1073/pnas.1534601100, 208769, 13679587.
38. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021. 10.1038/35082500, 11429595.
39. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679. 10.1038/nature05674, 17377531.
40. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507. 10.1038/ng.127, 2912221, 18443585.
41. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344. 10.1016/j.stem.2008.02.009, 2628721, 18397753.
42. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010, 107:163-224.
43. Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011, 76:369-374. 10.1101/sqb.2011.76.011296, 21960526.
44. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007, 13:820-827. 10.1038/nm1606, 17589519.
45. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001, 14:45-55. 10.1016/S1074-7613(01)00088-7, 11163229.
46. Ramirez A, Page A, Gandarillas A, Zanet J, Pibre S, Vidal M, Tusell L, Genesca A, Whitaker DA, Melton DW, Jorcano JL. A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis 2004, 39:52-57. 10.1002/gene.20025, 15124227.
47. Zanet J, Pibre S, Jacquet C, Ramirez A, de Alboran IM, Gandarillas A. Endogenous Myc controls mammalian epidermal cell size, hyperproliferation, endoreplication and stem cell amplification. J Cell Sci 2005, 118:1693-1704. 10.1242/jcs.02298, 15797928.
48. Clement-Ziza M, Gentien D, Lyonnet S, Thiery JP, Besmond C, Decraene C. Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling. BMC Genomics 2009, 10:246. 10.1186/1471-2164-10-246, 2700135, 19470167.
49. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D, Fassler R, Thiery JP, Glukhova MA. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008, 10:716-722. 10.1038/ncb1734, 2659707, 18469806.
50. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009, 347:70-78. 10.1016/j.jim.2009.06.008, 19567251.